Results 31 to 40 of about 36,008 (205)

Brain morphometric correlates of MAOA-uVNTR polymorphism in violent behavior

Revista Médica del Hospital General de México, 2015
Introduction: Violent behavior is influenced by genetic factors, and the MAOA-uVNTR polymorphism has been associated with violent behavior, specifically the low activity variant.
C. Romero-Rebollar, F. Ostrosky-Shejet, B. Camarena-Medellín, M.A. Bobes-León, K.X. Díaz-Galván, M.L. Pérez-López   +5 more
doaj   +1 more source

Monoamine Oxidase Inhibitors for Trichotillomania

Journal of Clinical Psychopharmacology, 2023
Abstract Purpose/Background Despite several decades of research, there are no US Food and Drug Administration–approved medications for trichotillomania or medications generally approved in other geographical jurisdictions.
Grant, Jon E., Chamberlain, Samuel
openaire   +4 more sources

Meeting report : Neuropathology and Neuropharmacology of Monoaminergic systems [PDF]

, 2014
The third EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” Annual Conference entitled “Neuropathology and ...
De Deurwaerdere, Philippe, Ramsay, Rona R.   +1 more
core   +1 more source

Effect of MAOA promoter polymorphism and neuropsychological performance on psychopathy traits

Revista Médica del Hospital General de México, 2015
Introduction: Psychopathy is a personality disorder characterized by affective and antisocial traits. The defining features of psychopathy are risk factors to present violent behavior.
C. Romero-Rebollar, F. Ostrosky-Shejet, B. Camarena-Medellín, M.A. Bobes-León, K.X. Díaz-Galván   +4 more
doaj   +1 more source

Monoamine Oxidase Contains a Redox-active Disulfide [PDF]

Journal of Biological Chemistry, 1998
Mitochondrial monoamine oxidases A and B (MAO A and MAO B) are ubiquitous homodimeric FAD-containing oxidases that catalyze the oxidation of biogenic amines. Both enzymes play a vital role in the regulation of neurotransmitter levels in brain and are of interest as drug targets.
S O, Sablin, R R, Ramsay
openaire   +2 more sources

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]

, 2015
In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani, Alessandro eStefani, Atticus H Hainsworth, Claudio eLiguori, Enrica eOlivola, Giacoma eAngileri, Mariangela ePierantozzi, Salvatore eGalati, Valentina eSaviozzi, Vincenza eD’Angelo   +9 more
core   +3 more sources

Computer-aided approach for the identification of lead molecules as the inhibitors of cholinesterase’s and monoamine oxidases: Novel target for the treatment of Alzheimer disease [PDF]

Journal of the Serbian Chemical Society
Molecular docking is a promising and reliable technology for the purpose of discovering lead compounds via virtual screening. In addition to allowing for the testing of a large number of compounds, it also allows for the determination of how the selected
Ejaz Syeda Abida, Aziz Mubashir, Fayyaz Ammara, Wani Tanveer A., Zargar Seema   +4 more
doaj   +1 more source

Examination of the Monoamine Oxidase A Gene Promoter on Motivation to Exercise and Levels of Voluntary Physical Activity [PDF]

, 2017
Purpose: The purpose of this study was to examine the genetic basis underlying voluntary exercise. Monoamine oxidase A (MAO-A) is an enzyme that acts on monoamine neurotransmitters, such as dopamine, to cause inactivation. There are several polymorphisms
Kinney, Erin M.
core   +4 more sources

A New Class of Monoamine Oxidase Inhibitors [PDF]

Journal of Neurochemistry, 1980
Abstract:Newly synthesized compounds have been found to inhibit mitochondrial monoamine oxidase (MAO) in mouse brain and rat liver. A series of 2‐acylamino‐3‐tert‐aminopropiophenones acted preferentially against MAO type B (2‐phenylethylamine as substrate), apparently irreversibly.
Vunnam, Ranga R., Bond, D., Schatz, Robert A., Radin, Norman S., Narasimhachari, N.   +4 more
openaire   +3 more sources

N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor [PDF]

, 2014
On the basis of N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (II, ASS234) and QSAR predictions, in this work we have designed, synthesized, and evaluated a number of new indole derivatives from which ...
Agbaba, D., Alcaro, S., Bautista-Aguilera, O.M., Chioua, M., De Andrés, L., Filipic, S., Marco-Contelles, J., Nikolic, K., Ortuso, F., Ramsay, R.R., Rodríguez-Franco, M.I., Samadi, A., Soriano, E., Yañez, M.   +13 more
core   +3 more sources